KalVista Pharmaceuticals, Inc. lost $3.69 per diluted share in fiscal year 2025. This represents a decrease of 7.3% from the prior fiscal year. The table below carries 12 fiscal years, from 2013 to 2025, and the quarters KalVista Pharmaceuticals, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$3.69
YoY-7.3%
Source SEC Filings (10-K/10-Q)Latest period Q4 FY2026, ended Mar 31, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
KALV EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was KalVista Pharmaceuticals, Inc.'s diluted earnings per share in fiscal year 2025?
KalVista Pharmaceuticals, Inc. lost $3.69 per diluted share in fiscal year 2025.
How fast is KalVista Pharmaceuticals, Inc.'s diluted earnings per share growing?
KalVista Pharmaceuticals, Inc. (KALV) diluted earnings per share fell by 7.3% year over year, from -$3.44 to -$3.69 in fiscal year 2025.
What was KalVista Pharmaceuticals, Inc.'s diluted earnings per share in the most recent quarter?
KalVista Pharmaceuticals, Inc. (KALV) reported -$0.43 in diluted earnings per share in Q4 2026. This represents an increase of 56.1% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what KalVista Pharmaceuticals, Inc. (KALV) reported on that line in every period on record.
